Kringle Pharma Yönetim

Yönetim kriter kontrolleri 1/4

Kringle Pharma CEO'su Kiichi Adachi, Dec2016 tarihinde atandı, in görev süresi 7.92 yıldır. şirketin hisselerinin 1.12% doğrudan sahiptir ve bu hisselerin değeri ¥ 64.14M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.9 yıl ve 5.9 yıldır.

Anahtar bilgiler

Kiichi Adachi

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	7.9yrs
CEO sahipliği	1.1%
Yönetim ortalama görev süresi	1.9yrs
Yönetim Kurulu ortalama görev süresi	5.9yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Not Too Worried About Kringle Pharma's (TSE:4884) Cash Burn Situation

Jun 15

We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth

Mar 02

CEO

Kiichi Adachi (57 yo)

7.9yrs

Görev süresi

Kiichi Adachi, Ph D., has been President at Kringle Pharma, Inc since December 27, 2016. Kiichi Adachi serves as a Director of Kringle Pharma, Inc. since December 2005.Kiichi Adachi was Research Scientist...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kiichi Adachi	President & Director	7.9yrs	Veri yok	1.12% ¥ 64.1m
Tomoya Shimojo	Chief Financial Officer & Director of Accounting and Corporate Planning	no data	Veri yok	Veri yok
Kunio Matsumoto	Chief Scientific Officer	no data	Veri yok	Veri yok
Koichi Murakami	GM of Corporate Planning Management Department & Director	no data	Veri yok	Veri yok
Daichika Hayata	GM of Pharmaceutical Development and Pharmaceutical Affairs Department & Director	1.9yrs	Veri yok	Veri yok
Yoshiyuki Kayano	Director & GM of Quality Assurance Department	less than a year	Veri yok	Veri yok

1.9yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: 4884 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.9 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kiichi Adachi	President & Director	18.9yrs	Veri yok	1.12% ¥ 64.1m
Koichi Murakami	GM of Corporate Planning Management Department & Director	2.9yrs	Veri yok	Veri yok
Daichika Hayata	GM of Pharmaceutical Development and Pharmaceutical Affairs Department & Director	1.9yrs	Veri yok	Veri yok
Yoshiyuki Kayano	Director & GM of Quality Assurance Department	less than a year	Veri yok	Veri yok
Kohichiro Yoshino	Independent Outside Director	5.9yrs	Veri yok	Veri yok
Akihiro Tomoyasu	Part Time Director	7.9yrs	Veri yok	Veri yok
Kazuto Ninomiya	Audit & Supervisory Board Member	5.9yrs	Veri yok	Veri yok
Masahiro Motokawa	Audit & Supervisory Board Member	5.9yrs	Veri yok	Veri yok
Yosuke Yamaguchi	Audit & Supervisory Board Member	5.9yrs	Veri yok	Veri yok
Masato Fukui	Independent Outside Director	3.9yrs	Veri yok	Veri yok

5.9yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4884 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.9 yıldır).

Kringle Pharma Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Kringle Pharma, Inc., Annual General Meeting, Dec 20, 2024

Kringle Pharma, Inc., Annual General Meeting, Dec 23, 2022

No independent directors

No independent directors

Recent updates

Kringle Pharma, Inc., Annual General Meeting, Dec 20, 2024

Kringle Pharma, Inc. to Report Fiscal Year 2024 Results on Nov 13, 2024

Kringle Pharma, Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2024

Here's Why We're Not Too Worried About Kringle Pharma's (TSE:4884) Cash Burn Situation

Second quarter 2024 earnings released: JP¥30.66 loss per share (vs JP¥29.35 loss in 2Q 2023)

We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth

First quarter 2024 earnings released: JP¥29.45 loss per share (vs JP¥29.18 loss in 1Q 2023)

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024

Kringle Pharma, Inc. to Report Q1, 2024 Results on Feb 09, 2024

Full year 2023 earnings released: JP¥158 loss per share (vs JP¥68.16 loss in FY 2022)

New minor risk - Shareholder dilution

Kringle Pharma, Inc. to Report Fiscal Year 2023 Results on Nov 13, 2023

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023

Third quarter 2023 earnings released: JP¥48.79 loss per share (vs JP¥2.57 profit in 3Q 2022)

New minor risk - Shareholder dilution

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023

First half 2023 earnings released: JP¥58.52 loss per share (vs JP¥70.08 loss in 1H 2022)

First quarter 2023 earnings released: JP¥29.18 loss per share (vs JP¥29.02 loss in 1Q 2022)

Kringle Pharma, Inc. Announces First Patient Enrollment in Phase III Clinical Study for the Treatment of Vocal Fold Scar

Kringle Pharma, Inc. Provides Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord Injury

Full year 2022 earnings released: JP¥68.16 loss per share (vs JP¥72.47 loss in FY 2021)

Kringle Pharma, Inc. to Report Q1, 2023 Results on Feb 10, 2023

Kringle Pharma, Inc. Provides Consolidated Earnings Guidance for Year Ending September 30, 2023

Kringle Pharma, Inc. Announces Initiation of Phase III Study of HGF in Vocal Fold Scar

Full year 2022 earnings released: JP¥68.16 loss per share (vs JP¥72.47 loss in FY 2021)

Kringle Pharma, Inc., Annual General Meeting, Dec 23, 2022

No independent directors

Kringle Pharma, Inc. Submits Clinical Trial Application

Kringle Pharma, Inc. Announces Jointly File A Patent Application with Keio University

Kringle Pharma, Inc. to Report Fiscal Year 2022 Results on Nov 14, 2022

Kringle Pharma, Inc. Provides Earnings Guidance for the Year Ending September 30, 2022

Third quarter 2022 earnings released: EPS: JP¥2.57 (vs JP¥12.50 loss in 3Q 2021)

Kringle Pharma, Inc. Updates on the Investigator-initiated Phase 2 Study in Patients with ALS

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2022

Second quarter 2022 earnings released: JP¥40.79 loss per share (vs JP¥12.50 loss in 2Q 2021)

Kringle Pharma, Inc. Provides an Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord Injury

No independent directors

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2022

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Kringle Pharma, Inc. Provides Earnings Forecast for the Fiscal Year Ending September 30, 2022

Kringle Pharma, Inc Announces Last Patient Out in Phase 2 Study of Kp-100It for the Treatment of Als

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2021

Kringle Pharma, Inc. to Report Q2, 2021 Results on May 14, 2021

Kringle Pharma, Inc. to Report Q1, 2021 Results on Feb 12, 2021

Kringle Pharma, Inc. has completed an IPO in the amount of ¥580 million.

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş